Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01573533
Recruitment Status : Completed
First Posted : April 9, 2012
Results First Posted : February 10, 2020
Last Update Posted : February 10, 2020
Sponsor:
Collaborators:
University Health Network, Toronto
National Institutes of Health (NIH)
Genentech, Inc.
Rush University Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Fernando Fervenza, Mayo Clinic

Brief Summary:
The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional therapies.

Condition or disease Intervention/treatment Phase
Primary Focal Segmental Glomerulosclerosis Biological: Rituximab Phase 2

Detailed Description:

This is a pilot trial to assess the safety, feasibility and efficacy of Rituximab therapy in 20 adult and pediatric patients with either steroid and/or calcineurin inhibitor resistant FSGS or with a significant intolerance or contraindication to the use of these agents. In addition to clinical criteria, elevated levels of suPAR will define inclusion. Changes in the baseline levels of the potential biomarkers (suPAR, as well as activation of beta-3 integrin) in response to treatment will be compared to clinical measures of efficacy.

Participants will have a screening/baseline visit to confirm eligibility within 6 weeks prior to the first of two Rituximab infusions (at Day 1 and Day 15). Participants will then attend follow up visits at 1, 3, 6 and 12 months after Rituximab treatment to assess adverse events and collect safety blood and urine samples.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β3 Integrin
Actual Study Start Date : October 2013
Actual Primary Completion Date : November 15, 2018
Actual Study Completion Date : November 15, 2018


Arm Intervention/treatment
Experimental: Rituximab Biological: Rituximab
Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.
Other Name: Rituxan®




Primary Outcome Measures :
  1. Changes in Proteinuria (With Stable Renal Function) [ Time Frame: Baseline, 12 months ]

    The amount of protein in excreted urine measured by grams per day (g/day). Remission status defined by the following criteria at 12 months:

    • Complete Remission - Proteinuria < 0.5 g/day
    • Partial Remission - Improvement in proteinuria by > 50% and to a level between 0.5-3.5g/day
    • Incomplete Remission - Improvement in proteinuria equal to or >50%, but residual proteinuria still >3.5g/day


Secondary Outcome Measures :
  1. Change in suPAR Levels [ Time Frame: Baseline, 1, 3, 6 and 12 months ]
    SuPAR concentrations will be determined by quantitative ELISA immunoassay reported in picograms per milliliters (pg/ml)

  2. Change in Activation of Podocyte β3 Integrin [ Time Frame: Baseline, 1, 3, 6, 12 months ]
    To quantitatively examine the effect of FSGS patient sera on podocyte β3 integrin activity, a human podocyte cell line is cultured at 37 degrees Celsius for 14 days for complete differentiation. The cells are then incubated in 5-10% of FSGS patient serum for 24 hours with recombinant suPAR protein as a positive control. Cells are fixed with 4% paraformaldehyde (PFA) and proceeded for immunofluorescence staining for AP5 and paxillin. After immunostaining, confocal images are taken to quantify the AP5 and paxillin intensity for each sample treatment. Paxillin signal is used to correct AP5 signal. The relative AP5 signal (AP5/paxillin ratio) from each patient serum is then normalized against that of normal blood donor included in each assay for final report.

  3. Number of Subjects With Complete or Partial Remission Following Treatment [ Time Frame: 12 months ]

    Total number of subjects with complete or partial remission following treatment using the following criteria:

    • Complete Remission - Proteinuria < 0.5 g/day
    • Partial Remission - Improvement in proteinuria by > 50% and to a level between 0.5-3.5g/day
    • Incomplete Remission - Improvement in proteinuria equal to or >50%, but residual proteinuria still >3.5g/day



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • FSGS involving native kidneys with a diagnostic biopsy performed within the last 3 years
  • Patients >6 years of age and < 80 years of age
  • suPAR > 3500 pg ml-1
  • Treatment with an ACEI and/or ARB as tolerated for at least 3 months prior to enrollment to with a target a systolic blood pressure ≤ 140 mmHg and a diastolic pressure ≤ 90 mmHg in adults and blood pressure readings less than the 95th percentile for age, gender and height in children in at least 75% of readings
  • Proteinuria ≥ 3.0 grams as measured by 24-hour urine collection in adults and urine protein:creatinine ratio ≥ 1.0 in the first morning urine in children, despite ACE inhibitor / ARB treatment as tolerated and a minimum of 8 weeks of prednisone therapy at ≥ 1 mg/kg/day, a trial of calcineurin inhibitor for=> 3 months or a contraindication/intolerance to such therapy (diabetes, osteoporosis/osteonecrosis, age >60, BMI ≥35)
  • Negative serum pregnancy test (for women of child bearing age)
  • Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months (1 year) after completion of the trial
  • Able and willing to give written informed consent and comply with study requirements

Exclusion Criteria:

  • Estimated GFR < 40 ml/min per1.73m2. The rationale is that patients with advanced renal failure may progress rapidly towards ESRD.
  • Collapsing variant of FSGS, as it is rare and has been associated with an aggressive course
  • Concurrent use of immunosuppressive therapy with the exceptions of prednisone 10 mg/day. Patients who are taking other immunosuppressive therapy, must be off immunosuppressive medications for equal to or > 3 months prior to enrollment into the study with the exception of patients demonstrating significant worsening of proteinuria (of >30% above baseline) during the washout period. These resistant patients can be treated after 1 month of washout due to the high likelihood of progression and/or lack of delayed (previous) immunosuppression effect.
  • Patients with medical conditions that may cause FSGS (e.g. HIV, lymphoma, heroin use) or have a secondary form of FSGS due to hyperfiltration injury (massive obesity, vesicoureteral reflux, or renal mass reduction)
  • Type 1 or type 2 diabetes mellitus as diabetic glomerulosclerosis may be contributing to proteinuria in these patients
  • History of serious recurrent or chronic infection
  • Presence or suspicion of active infection including TB, HIV, Hepatitis B and HCV with positive tests for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Hepatitis B virus (HBV), Hepatitis C serology, HIV serology or a positive TB skin test, which require further investigation to rule out active disease (ie. chest x-ray)
  • Known active infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks or oral antibiotics within 2 weeks of the study initiation
  • Low immunoglobulins (level to be based on age)
  • Absolute neutrophil count < 1.5 x103/mL
  • Patients in receipt of a live vaccine within 4 weeks of the study initiation
  • Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  • Previous Treatment with a B-cell depleting antibody
  • History of severe allergic reactions to humanized or murine monoclonal antibodies
  • Treatment with any investigational agent within 4 weeks of the study initiation
  • History of major psychiatric disorder, drug or alcohol abuse within the previous 6 months
  • Any other disease, metabolic dysfunction, physical examination finding or clinical laboratory that provides a reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01573533


Locations
Layout table for location information
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Minnesota
Mayo Clinic College of Medicine
Rochester, Minnesota, United States, 55905
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
University Health Network
Toronto, Ontario, Canada, M5G 2N2
Sponsors and Collaborators
Mayo Clinic
University Health Network, Toronto
National Institutes of Health (NIH)
Genentech, Inc.
Rush University Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Layout table for investigator information
Principal Investigator: Michelle Hladunewich, MD, MSc, BSc University Health Network, Sunnybrook Health Sciences Centre
Principal Investigator: Fernando C Fervenza, MD, PhD Mayo Clinic
  Study Documents (Full-Text)

Documents provided by Fernando Fervenza, Mayo Clinic:

Additional Information:
Layout table for additonal information
Responsible Party: Fernando Fervenza, PI, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01573533    
Other Study ID Numbers: 12-005640
U54DK083912 ( U.S. NIH Grant/Contract )
First Posted: April 9, 2012    Key Record Dates
Results First Posted: February 10, 2020
Last Update Posted: February 10, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Fernando Fervenza, Mayo Clinic:
Treatment Resistant Idiopathic FSGS
Glomerulosclerosis
Proteinuria
Rituximab
Additional relevant MeSH terms:
Layout table for MeSH terms
Glomerulosclerosis, Focal Segmental
Glomerulonephritis
Nephritis
Kidney Diseases
Urologic Diseases
Rituximab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents